ENDRA Life Sciences Inc (NDRA) - Net Assets
Based on the latest financial reports, ENDRA Life Sciences Inc (NDRA) has net assets worth $171.38K USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.96 Million) and total liabilities ($1.79 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read NDRA total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $171.38K |
| % of Total Assets | 8.73% |
| Annual Growth Rate | 15.51% |
| 5-Year Change | -64.29% |
| 10-Year Change | 922.92% |
| Growth Volatility | 145.98 |
ENDRA Life Sciences Inc - Net Assets Trend (2014–2024)
This chart illustrates how ENDRA Life Sciences Inc's net assets have evolved over time, based on quarterly financial data. Also explore ENDRA Life Sciences Inc asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for ENDRA Life Sciences Inc (2014–2024)
The table below shows the annual net assets of ENDRA Life Sciences Inc from 2014 to 2024. For live valuation and market cap data, see ENDRA Life Sciences Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.56 Million | -54.76% |
| 2023-12-31 | $5.66 Million | -21.45% |
| 2022-12-31 | $7.20 Million | -33.19% |
| 2021-12-31 | $10.78 Million | +50.42% |
| 2020-12-31 | $7.17 Million | +50.59% |
| 2019-12-31 | $4.76 Million | -23.81% |
| 2018-12-31 | $6.25 Million | +18.44% |
| 2017-12-31 | $5.28 Million | +690.25% |
| 2016-12-31 | $-893.77K | -457.08% |
| 2015-12-31 | $250.30K | -58.65% |
| 2014-12-31 | $605.33K | -- |
Equity Component Analysis
This analysis shows how different components contribute to ENDRA Life Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9597420000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $53.00 | 0.00% |
| Other Components | $106.00 Million | 4139.97% |
| Total Equity | $2.56 Million | 100.00% |
ENDRA Life Sciences Inc Competitors by Market Cap
The table below lists competitors of ENDRA Life Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Alaunos Therapeutics Inc
NASDAQ:TCRT
|
$5.83 Million |
|
Betacom S.A.
WAR:BCM
|
$5.83 Million |
|
Gayatri Highways Limited
NSE:GAYAHWS
|
$5.83 Million |
|
Warehouse REIT plc
LSE:WHR
|
$5.84 Million |
|
Gentrogroup Co. Ltd.
KQ:083660
|
$5.82 Million |
|
CHINA HEALTH GRP HD-10
F:VNL1
|
$5.82 Million |
|
mTouche Technology Bhd
KLSE:0092
|
$5.82 Million |
|
Errawarra Resources Ltd
AU:ERW
|
$5.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ENDRA Life Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,658,989 to 2,560,366, a change of -3,098,623 (-54.8%).
- Net loss of 11,507,947 reduced equity.
- Dividend payments of 5,233 reduced retained earnings.
- New share issuances of 1,148,470 increased equity.
- Other comprehensive income decreased equity by 5,233.
- Other factors increased equity by 7,271,320.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.51 Million | -449.46% |
| Dividends Paid | $5.23K | -0.2% |
| Share Issuances | $1.15 Million | +44.86% |
| Other Comprehensive Income | $-5.23K | -0.2% |
| Other Changes | $7.27 Million | +284.0% |
| Total Change | $- | -54.76% |
Book Value vs Market Value Analysis
This analysis compares ENDRA Life Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.17x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.25x to 2.17x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $19.76 | $4.95 | x |
| 2015-12-31 | $1.28 | $4.95 | x |
| 2016-12-31 | $-4.58 | $4.95 | x |
| 2017-12-31 | $26.95 | $4.95 | x |
| 2018-12-31 | $27.74 | $4.95 | x |
| 2019-12-31 | $12.70 | $4.95 | x |
| 2020-12-31 | $7.47 | $4.95 | x |
| 2021-12-31 | $5.27 | $4.95 | x |
| 2022-12-31 | $3.73 | $4.95 | x |
| 2023-12-31 | $3.31 | $4.95 | x |
| 2024-12-31 | $2.28 | $4.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ENDRA Life Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -449.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.74x
- Recent ROE (-449.46%) is below the historical average (-262.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -360.28% | -389.89% | 0.80x | 1.16x | $-2.24 Million |
| 2015 | -910.59% | -161.64% | 2.90x | 1.94x | $-2.30 Million |
| 2016 | 0.00% | -538.30% | 1.05x | 0.00x | $-2.69 Million |
| 2017 | -101.92% | -1529.19% | 0.06x | 1.16x | $-5.90 Million |
| 2018 | -156.79% | -158669.60% | 0.00x | 1.16x | $-10.42 Million |
| 2019 | -279.50% | 0.00% | 0.00x | 1.51x | $-13.78 Million |
| 2020 | -163.55% | 0.00% | 0.00x | 1.22x | $-12.44 Million |
| 2021 | -104.14% | 0.00% | 0.00x | 1.19x | $-12.31 Million |
| 2022 | -182.93% | 0.00% | 0.00x | 1.29x | $-13.90 Million |
| 2023 | -177.77% | 0.00% | 0.00x | 1.19x | $-10.63 Million |
| 2024 | -449.46% | 0.00% | 0.00x | 1.74x | $-11.76 Million |
Industry Comparison
This section compares ENDRA Life Sciences Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $694,923,903
- Average return on equity (ROE) among peers: -98.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ENDRA Life Sciences Inc (NDRA) | $171.38K | -360.28% | 10.46x | $5.82 Million |
| Agilent Technologies Inc (A) | $5.90 Billion | 21.85% | 1.01x | $32.42 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.49 Million | -115.35% | 0.92x | $7.19 Million |
| Applied DNA Sciences Inc (APDN) | $5.71 Million | -223.57% | 0.99x | $3.99 Million |
| Biodesix Inc (BDSX) | $-228.54 Million | 0.00% | 0.00x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $9.85 Million |
| Biocept Inc. (BIOCQ) | $11.20 Million | -224.43% | 0.58x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $30.47 Million | -271.32% | 5.29x | $3.21 Billion |
| Burning Rock Biotech Ltd (BNR) | $768.41 Million | -85.07% | 0.35x | $154.44 Million |
| CareDx Inc (CDNA) | $465.88 Million | -6.58% | 0.22x | $1.00 Billion |
| Check Cap Ltd (CHEK) | $10.41 Million | -84.81% | 0.18x | $9.42 Million |
About ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source comprising radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic… Read more